Protalix BioTherapeutics/$PLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Protalix BioTherapeutics
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Ticker
$PLX
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
213
ISIN
US74365A3095
Website
PLX Metrics
BasicAdvanced
$136M
35.51
$0.05
-0.05
-
Price and volume
Market cap
$136M
Beta
-0.05
52-week high
$3.10
52-week low
$0.82
Average daily volume
1.2M
Financial strength
Current ratio
2.488
Quick ratio
1.621
Long term debt to equity
8.43
Total debt to equity
11.582
Interest coverage (TTM)
6.83%
Management effectiveness
Return on assets (TTM)
3.53%
Return on equity (TTM)
10.42%
Valuation
Price to earnings (TTM)
35.505
Price to revenue (TTM)
2.101
Price to book
2.96
Price to tangible book (TTM)
2.96
Price to free cash flow (TTM)
-80.384
Growth
Revenue change (TTM)
0.18%
Earnings per share change (TTM)
-23.34%
3-year revenue growth (CAGR)
11.50%
3-year earnings per share growth (CAGR)
-55.18%
What the Analysts think about PLX
Analyst ratings (Buy, Hold, Sell) for Protalix BioTherapeutics stock.
PLX Financial Performance
Revenues and expenses
PLX Earnings Performance
Company profitability
PLX News
AllArticlesVideos
Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth
Proactive Investors·2 weeks ago
Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline
Seeking Alpha·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Protalix BioTherapeutics stock?
Protalix BioTherapeutics (PLX) has a market cap of $136M as of May 23, 2025.
What is the P/E ratio for Protalix BioTherapeutics stock?
The price to earnings (P/E) ratio for Protalix BioTherapeutics (PLX) stock is 35.51 as of May 23, 2025.
Does Protalix BioTherapeutics stock pay dividends?
No, Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Protalix BioTherapeutics dividend payment date?
Protalix BioTherapeutics (PLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Protalix BioTherapeutics?
Protalix BioTherapeutics (PLX) has a beta rating of -0.05. This means that it has an inverse relation to market volatility.